[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100606149","comparing-3d-and-2d-views-in-biportal-spine-surgery-a-pilot-simulation-study-100606149",false,"NCT07171801","Comparing 3D and 2D Views in Biportal Spine Surgery: A Pilot Simulation Study","3D vs. 2D Unilateral Biportal Endoscopic Spine Surgery: A Randomized Blinded Crossover Pilot Simulation Study","Inclusion Criteria:\n\n* Enrolled in the neurosurgical residency or fellowship program at the Department of Neurosurgery, Cantonal Hospital of St. Gallen, Switzerland\n* Completion of basic neurosurgical training modules, including introductory endoscopic handling\n* Age ≥ 18 years\n* Willingness and ability to provide informed consent\n\nExclusion Criteria:\n\n* Prior substantial experience with three-dimensional (3D) endoscopy (defined as \\> 5 independent procedures performed with 3D visualization systems)\n* Ocular or neurological conditions impairing stereopsis, fine motor control, or safe endoscope handling\n* Inability or unwillingness to complete the simulation protocol\n* Declined participation",true,"ALL","18 Years",{"count":20,"type":21},6,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to compare three-dimensional (3D) and two-dimensional (2D) visualization in biportal endoscopic spine surgery using a simulated environment. Surgeons will perform standardized tasks on a spine model while using either 3D or 2D endoscopic systems. The goal is to determine whether 3D technology can improve precision, efficiency, and movement control during surgery. The study uses a randomized, blinded, crossover design to ensure objective results and may help guide future training and technology use in spinal endoscopy.",[27,28,29,30,31,32],"Spinal Diseases","Endoscopy Simulation","Lumbar Vertebrae","Randomized Controlled Trial","Three-Dimensional","Simulation Training","NOT_YET_RECRUITING","2025-09-15",{"date":36,"type":37},"2025-09-16","ACTUAL",{"date":39,"type":21},"2025-10-01",{"date":41,"type":21},"2025-12-01",{"name":43,"class":44},"Felix Corr","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100606852","phase-4-comparison-of-perineural-dexamethasone-versus-dexmedetomidine-as-adjuvants-to-erector-spinae-plane-block-in-lumbar-spine-surgery-a-randomized-double-blind-controlled-trial-100606852","NCT07180940","Comparison of Perineural Dexamethasone Versus Dexmedetomidine as Adjuvants to Erector Spinae Plane Block in Lumbar Spine Surgery: A Randomized, Double-blind, Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to N\u002FA (no limit)\n* Scheduled for elective lumbar spine surgery (e.g., decompression or fusion) via posterior approach\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body weight ≥ 50 kg\n* Ability to provide written informed consent\n* Expected postoperative hospitalization of at least 48 hours\n\nExclusion Criteria:\n\n* Known allergy or contraindication to ropivacaine, dexamethasone, or dexmedetomidine\n* Infection at or near the site of block placement\n* Coagulation disorders or current use of anticoagulant therapy (not discontinued per guidelines)\n* Chronic opioid use or opioid dependence\n* Neurological or psychiatric disorders interfering with pain assessment\n* Diabetes mellitus with poorly controlled glycemia (e.g., HbA1c \\> 8%)\n* Severe hepatic or renal dysfunction\n* Body mass index (BMI) \\> 40 kg\u002Fm²\n* Pregnancy or breastfeeding\n* Refusal or inability to cooperate with the study protocol",{"count":52,"type":21},150,[54],"PHASE4","This clinical study aims to determine which of two medications-dexamethasone or dexmedetomidine-works better and is safer when used together with a local anesthetic (ropivacaine) in a type of nerve block called the erector spinae plane block (ESPB). This block helps reduce pain after lumbar spine surgery.",[57,27],"Spine Disease","RECRUITING","2025-09-12",{"date":61,"type":37},"2025-09-18",{"date":63,"type":37},"2025-09-01",{"date":65,"type":21},"2026-12-31",{"name":67,"class":44},"Poznan University of Medical Sciences",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":68},"100476486","prevention-of-thromboembolism-using-apixaban-vs-enoxaparin-following-spinal-cord-injury-100476486","NCT05484557","Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury","Inclusion Criteria:\n\n* spinal cord injury (traumatic of not traumatic), Hebrew speaker.\n\nExclusion Criteria:\n\n* contra-indication for anticoagulant treatment\n* concomitant treatment with any other anticoagulant\n* anticoagulant treatment needed for indications other than VTE prevention following spinal cord injury\n* active clinically significant bleeding\n* any lesion or condition considered a significant risk factor for major bleeding.\n* hepatic disease associated with coagulopathy and clinically relevant bleeding risk\n* pregnancy or breast-feeding\n* heart valve related issues\n* galactose intolerance\n* active cancer\n* patients who require thrombolysis or pulmonary embolectomy\n* patients with renal impairment\n* sensitivity to excipients of the medication\n* anti phospholipid syndrome\n* prosthetic heart valve\n* acute ischemic stroke",{"count":76,"type":21},60,[24],"Currently, Enoxaparin is the usual prophylactic anticoagulant treatment at the acute and sub-acute phases of spinal cord injury (SCI). Patients at the sub-acute phase of SCI (rehabilitation) will be given either Enoxaparin 40 mg\u002Fday (control) or Apixaban 2.5-5 mg twice a day. Apixaban dose will be determined by the treating physician. Treatment will be continued for either 6 or 12 weeks following injury (for AIS grades C-D and A-B respectively).\n\nEndpoints: Venous thromboembolism will be evaluated by D-Dimer test every 2 weeks and an ultrasound doppler at the beginning and the end of the treatment. Bleeding events will be recorded and hematocrit will be monitored every two weeks.",[80,27],"Spinal Cord Injuries","2025-05-06",{"date":83,"type":37},"2025-05-09",{"date":85,"type":37},"2023-09-06",{"date":87,"type":21},"2026-02",{"name":89,"class":44},"Loewenstein Hospital"]